Selective vasopressin, angiotensin II, or dual receptor blockade with developing congestive heart failure

Journal of Pharmacology and Experimental Therapeutics

Volumn 293, Issue 3, 2000, Pages 852-860

  Clair, Mark J ^a   King, Mary K ^a   Goldberg, Aron T ^a   Hendrick, Jennifer W ^a   Nisato, Riccardo ^a   Gay, David M ^a   Morrison, Allison E ^a   McElmurray III, James H ^a   Krombach, R Stephen ^a   Bond, Brian R ^a   Cazaubon, Catherine ^b   Nisato, Dino ^b   Spinale, Francis G ^a,c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b SANOFI   (France)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; IRBESARTAN; RELCOVAPTAN; VASOPRESSIN V1 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE COURSE; DRUG RECEPTOR BINDING; HEART LEFT VENTRICLE CONTRACTILITY; HEART LEFT VENTRICLE FUNCTION; HEART PACING; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HEART WORK; NONHUMAN; PRIORITY JOURNAL; SWINE;

ANGIOTENSIN II; ANIMALS; ATRIAL NATRIURETIC FACTOR; BLOOD PRESSURE; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; MALE; MYOCARDIAL CONTRACTION; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN; RECEPTORS, VASOPRESSIN; SODIUM; SWINE; VASOPRESSINS; VENTRICULAR FUNCTION, LEFT;

EID: 0034086486     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Arnolda L, McGrath BP and Johnston CI (1991) Systemic and regional effects of vasopressin and angiotensin in acute left ventricular failure. Am J Physiol 260: H499-H506.
2. Benedict CR, Weiner DH, Johnstone DE, Bourassa MG, Ghali JK, Nicklas J, Kirlin P, Greenberg B, Quinones MA and Yusuf S (1993) Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: Results of the Studies of Left Ventricular Dysfunction (SOLVD) Registry. J Am Coll Cardiol 22:146A-133A.
3. Bichet DG (1994) Molecular and cellular biology of vasopressin and oxytocin receptors and action in the kidney. Curr Opin Nephrol Hypertens 3:45-53.
4. Brasch H, Sieroslawski L and Dominiak P (1993) Angiotensin II increases norepinephrine release from atria by acting on angiotensin subtype 1 receptors. Hypertension 22:699-704.
5. Burrell L, Phillips P, Risvanis J, Chan R, Aldred K and Johnston C (1998) Long-term effects of nonpeptide vasopressin V2 antagonist OPC-31260 in heart failure in the rat. Am J Physiol 275:H176-H182.
6. Burrell LM, Phillips PA, Rolls KA, Buxton SF, Johnston CI and Liu JJ (1994) Vascular responses to vasopressin antagonists in man and rat. Clin Sci 87:389-395.
7. 1 subtype angiotensin II receptor antagonist. J Pharmacol Exp Ther 265:826-833.
8. Clair MJ, Krombach RS, Hendrick JW, Houck WV, Hebbar L, Kribbs SB, Rios G, Whitebread S, Mukherjee R, de Gasparo M and Spinale FG (1998) AT1 angioten-sin II receptor inhibition in pacing-induced heart failure: Effects on left ventricular performance and regional blood flow patterns. J Card Fail 4:311-323.
9. Colan SD, Borrow KM and Neuman A (1984) Left-ventricular end-systolic wall stress-velocity of fiber shortening relation: A load independent index of myocardial contractility. J Am Coll Cardiol 4:715-724.
10. Goldsmith JR, Francis GS, Cowley AW, Levine T and Cohn JN (1983) Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol 1:1385-1390.
11. 1 receptor inhibition, and combination therapy with pacing induced heart failure: Effects on left ventricular performance and regional blood flow patterns. Cardiovasc Res 38:631-645.
12. Manning M, Stoev S, Chan WY and Sawyer WH (1993) Receptor-specific antagonists of vasopressin and oxytocin: A current perspective. Ann NY Acad Sci 689:219-232.
13. Mulinari RA, Gavras I, Wang Y, Franco R and Gavras H (1990) Effects of a vasopressin antagonist with combined antipressor and antiantidiuretic activities in rats with left ventricular dysfunction. Circulation 81:308-311.
14. Naitoh M, Suzuki H, Murakami M, Matsumoto A, Ichihara A, Nakamoto H, Oka K, Yamamura Y and Saruta T (1994) Effects of oral AVP antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am J Physiol 267: H2245-H2254.
15. Nishikimi T, Kawano Y, Saito Y and Matsuoka H (1996) Effect of long-term treatment with selective vasopressin V1 and V2 antagonist on the development of heart failure in rats. J Cardiovasc Pharmacol 27:275-282.
16. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PI, on behalf of the ELITE Study Investigators (1997) Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349:747-752.
17. Riegger GAJ and Liebau G (1982) The renin-angiotensin-aldosterone system, anti-diuretic hormone and sympathetic nerve activity in an experimental model of congestive heart failure in the dog. Clin Sci (Lond) 62:465-469.
18. Ross J Jr (1976) Afterload mismatch and preload reserve: A conceptual framework for the analysis of ventricular function. Prog Cardiovasc Dis 18:255-264.
19. 1a receptors. J Clin Invest 92:224-231.
20. Spinale FG (1995) Pacing tachycardia-induced congestive heart failure. Heart Fail 11:219-232.
21. Spinale FG, de Gasparo M, Whitebread S, Hebbar L, Clair MJ, Melton M, Krombach RS, Mukherjee R and Iannini JP (1997a) Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing induced heart failure. I. Effects on left ventricular performance and neurohormonal systems. Circulation 96:2385-2396.
22. Spinale FG, Fullbright BM, Mukherjee R, Tanaka R, Hu J, Crawford FA and Zile MR (1992) Relation between ventricular and myocyte function with tachycardia-induced cardiomyopathy. Circ Res 71:174-187.
23. Spinale FG, Holzgrefe HH, Mukherjee R, Hird RB, Walker JD, Arnim AE, Powell JR and Koster WH (1995) Angiotensin converting enzyme inhibition and the progression of congestive cardiomyopathy: Effects on left ventricular and myocyte structure and function. Circulation 92:562-568.
24. Spinale FG, Mukherjee R, Iannini JP, Whitebread S, Hebbar L, Clair MJ, Melton DM, Cox MH, Thomas PB and de Gasparo M (1997b) Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing induced heart failure. II. Effects on myocyte contractile processes. Circulation 96:2397-2406.
25. Stebbins CL, Symons DJ, McKirnan MD and Hwang FFY (1994) Factors associated with vasopressin release in exercising swine. Am J Physiol 35:R118-R124.
26. Szatalowicz VL, Arnold PE, Chaimovitz C, Bichet D, Beri T and Schrier RW (1981) Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med 305:262-266.
27. Tanaka R, Fulbright BM, Mukherjee R, Burchell SA, Crawford FA, Zile MR and Spinale FG (1993) The cellular basis for the blunted response to β-adrenergic stimulation in supraventricular tachycardia-induced cardiomyopathy. J Mol Cell Cardiol 25:1215-1233.
28. The CONSENSUS Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Eng J Med 316:1429-1435.
29. The SOLVD Investigators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325:293-302.
30. Thomas PB, Liu EC, Webb ML, Mukherjee R, Hebbar L and Spinale FG (1997) Exogenous effects and endogenous production of endothelin in cardiac myocytes: potential significance in heart failure. Am J Physiol 271:H2629-H2637.
31. Tomita M, Spinale FG, Crawford FA and Zile MR (1991) Changes in left ventricular volume, mass and function during development and regression of supraventricular tachycardia induced cardiomyopathy: Disparity between recovery of systolic vs diastolic function. Circulation 83:635-644.
32. Travill CM, Williams TDM, Pate P, Song G, Chalmers J, Lightman SL, Sutton R and Noble MIM (1992) Hemodynamic and neurohormonal response in heart failure produced by rapid ventricular pacing. Cardiovasc Res 26:783-790.
33. Wang Y, Franco R, Gavras I and Gavras H (1991) Effects of chronic administration of a vasopressin antagonist with combined antivasopressor and antiantidiuretic activities in rats with left ventricular dysfunction. J Lab Clin Med 117:313-318.
34. Wei CM, Lerman A, Rodeheffer RJ, McGregor CGA, Brandt RR, Wright S, Heublein DM, Kao PC, Edwards WD and Burnett JC (1994) Endothelin in human congestive heart failure. Circulation 89:1580-1586.
35. Yamaguchi K, Sakaguchi T and Kamoi K (1982) Central role of angiotensin in the hyperosmolality-and hypovolaemia-induced vasopressin release in conscious rats. Acta Endocrinol 101:524-530.
36. Zimmerman BG, Gomer SK and Liao JC (1972) Action of angiotensin on vascular adrenergic nerve endings: Facilitation of norepinephrine release. Fed Proc 31: 1344-1350.